News

Mast is pleased to announce the launch of NEW additions to the MASTDISCS^® AST range for EUCAST and CLSI methodology:

Mast Group Ltd. are pleased to announce the expansion of their molecular product portfolio with the launch of the New MAST ISOPLEX^® CRE-ART  kit for the rapid molecular detection of carbapenemase producing organisms (CPOs).

Mast are pleased to announce the launch of the NEW  MASTDISCS^® Combi  ESBL Detection Set (EUCAST) with the new disc potencies as recommended by EUCAST for the reliable detection of ESBL producing Enterobacterales.

MAST^® ASSURE Bacterial Agglutinating Antisera products are a comprehensive range of polyvalent and monovalent diagnostic antisera for bacterial identification.

Mast Group Ltd. exhibited at the Institute of Biomedical Science Congress 2019 at the International Convention Centre in Birmingham 22^nd – 25^th September 2019, and it proved to be a triumph!

Mast Group Ltd has been a manufacturer of antibiotic susceptibility test (AST) products since 1957 and continues to be at the forefront of developments in this field. 

Since the launch of new additions to the MASTDISCS^® range – Meropenem-Vaborbactam 20-10µg (MEV30C), Eravacycline 20µg (ERV20C) and Delafloxacin 5µg (DLX5C) at ECCMID 2019, we have had a positive response to these novel compounds for the treatment of complicated infections.

Mast Group Ltd. has been manufacturing AST discs for over 60 years, with a history of experience, quality and innovation, the expansion of the portfolio has resulted in the most comprehensive range available world-wide.

Mast Group Ltd. exhibited at ECCMID 2019 in Amsterdam, Netherlands 13^th – 16^th April 2019, and it proved to be a huge success!